Release date: 2009-08-14
In a groundbreaking move, the University of Tokyo Affiliated Hospital is set to begin a clinical trial in late August, focusing on the use of transgenic viruses to treat malignant brain tumors. This initiative marks the first such effort in Japan and could potentially revolutionize cancer treatment. The study aims to evaluate the effectiveness of this innovative therapy, offering hope to patients with one of the most aggressive forms of brain cancer.
The trial will specifically target glioblastoma, a highly malignant type of brain tumor known for its rapid growth and short disease progression. Standard treatment usually involves surgery followed by radiation and chemotherapy. However, even with these interventions, the average survival time is only around 12 to 14 months, and if the tumor recurs, life expectancy drops to just 5 to 9 months. Given the severity of this condition, researchers are exploring new and more effective treatment options.
To address this challenge, scientists have modified a herpes virus, making it more selective in targeting cancer cells while minimizing harm to healthy tissue. This genetically engineered virus is designed to focus its "attack" on the tumor, leveraging the body's natural defenses against cancer. By doing so, the treatment aims to be both safer and more effective than traditional methods.
The clinical trial will involve patients who have experienced a recurrence of glioblastoma. Participants will receive two injections of the transgenic herpes virus into the tumor site over a two-week period. Researchers will closely monitor the effects, including changes in tumor size and any signs of neurological complications. The entire study is expected to last for two years, providing valuable insights into the long-term potential of this approach.
Experts in the field believe that gene-modified viral therapies may hold the key to treating some of the most challenging cancers in the future. In 2005, American researchers published findings in *Cancer Research* showing that a similar approach significantly extended the lifespan of mice with human brain tumors without harming healthy cells. This promising result has fueled further interest in exploring the therapeutic potential of viruses in oncology.
As this trial moves forward, it represents a significant step toward developing more personalized and effective cancer treatments. With continued research and innovation, the future of brain tumor therapy looks increasingly hopeful for patients and medical professionals alike.
Pollock Fillet,Petite Hake Fillets,Filleting Hake,Cape Hake Fillets
ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com